Abstract
Chemical conjugates between recombinant single-chain urokinase-type plasminogen activator (rscu-PA) and a murine monoclonal antibody directed against fragment D-dimer of cross-linked human fibrin (MA-15C5), rscu-PA/MA-15C5, and between rscu-PA and a control monoclonal antibody (MA-1C8), rscu-PA/MA-1C8, were produced by cross-linking with N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP). In an in vitro system composed of a [125 I]fibrin-labeled baboon plasma clot immersed in autologous citrated plasma, dose- and time-dependent lysis was obtained with a ratio of the potencies of free and conjugated rscu-PA similar to that in human plasma: 50% lysis in 2 hours required 4.3 micrograms/ml rscu-PA, 1.0 microgram/ml urokinase-type plasminogen activator (u-PA) equivalent rscu-PA/MA-15C5, or 15 micrograms/ml u-PA equivalent rscu-PA/MA-1C8. The thrombolytic and pharmacokinetic properties of rscu-PA and of rscu-PA/MA-15C5 were compared in baboons with a 0.8-1.0 ml [125 I]fibrin-labeled autologous blood clot produced in a femoral vein. Continuous intravenous infusion of these compounds during a 2-hour period resulted in dose- and time-dependent lysis. The thrombolytic potency of rscu-PA/MA-15C5 was 3.0 +/- 0.5 times higher (50% lysis w...Continue Reading
References
Nov 1, 1986·Circulation·F Van de WerfD Collen
Oct 20, 1989·European Journal of Biochemistry·M DewerchinD Collen
Apr 1, 1989·Radiology·Y HashimotoD Collen
Jul 1, 1986·European Journal of Biochemistry·P HolvoetD Collen
Apr 1, 1987·Seminars in Thrombosis and Hemostasis·H R LijnenD C Collen
Apr 5, 1988·Biochemistry·C de VriesH Pannekoek
Dec 1, 1988·Thrombosis Research·H R LijnenD Gheysen
Apr 1, 1987·Journal of Molecular and Cellular Cardiology·C BodeE Haber
Aug 23, 1985·Science·C BodeE Haber
Jun 27, 1983·Annals of the New York Academy of Sciences·P J Gaffney
Jun 1, 1984·The Journal of Clinical Investigation·V GurewichR Greenlee
Mar 1, 1982·The Journal of Clinical Investigation·C KorningerD Collen
Apr 9, 1981·Nature·R A SmithJ Green
Apr 1, 1957·Acta Haematologica·A CLAUSS
May 1, 1963·Clinica Chimica Acta; International Journal of Clinical Chemistry·C VERMYLENM VERSTRAETE
Citations
Apr 1, 1992·Cardiovascular Drugs and Therapy·M Verstraete
Nov 1, 1993·Cardiovascular Drugs and Therapy·R C Becker
Jan 1, 1992·Biotherapy·R Bos, W Nieuwenhuizen
Jan 1, 1993·Biotechnology Advances·H R Lijnen, D Collen
Apr 1, 1991·Current Opinion in Biotechnology·G R Larsen, E S Barnathan
May 1, 1992·Trends in Cardiovascular Medicine·I M LubinM S Runge
Dec 19, 2000·Enzyme and Microbial Technology·P JiangB Ru
Mar 1, 1991·MNA Accent·K Barvels
Apr 1, 1992·European Journal of Biochemistry·A M VandammeD Collen
Dec 1, 1994·Cardiovascular Drugs and Therapy·M Verstraete, H R Lijnen
Dec 4, 1992·Annals of the New York Academy of Sciences·V P Torchilin
Dec 4, 1992·Annals of the New York Academy of Sciences·E HaberM S Runge
Dec 4, 1992·Annals of the New York Academy of Sciences·H R Lijnen, D Collen
Jan 3, 1992·The American Journal of Cardiology·D Collen
Jan 25, 2017·Frontiers of Medicine·Melvin E Klegerman
Jul 1, 1992·Bioconjugate Chemistry·C BodeE Haber
Sep 1, 1991·Bioconjugate Chemistry·M Dewerchin, D Collen
Sep 1, 1991·Bioconjugate Chemistry·D J HayzerM S Runge
Mar 1, 1991·British Journal of Haematology·H R Lijnen, D Collen
Sep 1, 1991·Progress in Cardiovascular Diseases·D CollenH K Gold